Maravai Lifesciences Holdings, Inc. (MRVI) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Maravai Lifesciences reported revenue of $185.7M, down 28.3% from $259.2M the year before. Net income was -$130.8M (a -70.4% net margin), or -$0.90 per diluted share. Gross margin was 18.3% and operating margin was -115.9%. Operating activities generated -$57.6M of cash, leaving -$70.7M of free cash flow. At fiscal year end, Maravai Lifesciences held $770.6M in total assets against $397.9M in total liabilities, including $216.9M of cash and equivalents.
Open the full interactive Maravai Lifesciences financials → Quarterly statements, key ratios, valuation history and price charts.
Maravai Lifesciences Key Stats
| Share Price | $6.53 |
|---|---|
| Market Cap | $966.4M |
| Revenue YoY Growth | -28.3% |
| 52-Week Range | $2.83 – $9.00 |
| Shares Outstanding | 148.0 million (basic, 2026 Q2) |
Maravai Lifesciences Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $799.2M | $883.0M | $288.9M | $259.2M | $185.7M |
| Cost of Goods Sold | $244.6M | $308.8M | $320.6M | $494.8M | $249.3M |
| Gross Profit | $658.7M | $714.0M | $140.2M | $108.3M | $34.0M |
| Operating Income | $554.6M | $574.2M | -$31.6M | -$235.6M | -$215.3M |
| Pre-Tax Income | $530.8M | $551.5M | $617.7M | -$261.5M | -$235.0M |
| Income Tax | $61.5M | $60.8M | $756.1M | -$1.9M | -$4.2M |
| Net Income | $182.0M | $220.2M | -$119.0M | -$144.8M | -$130.8M |
| Diluted EPS | $1.56 | $1.67 | -$0.90 | -$1.05 | -$0.90 |
Maravai Lifesciences Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $41.6M | $49.9M | $65.8M | $51.4M |
| Net Income | -$25.6M | -$35.7M | -$3.7M | -$12.4M |
| Diluted EPS | -$0.18 | -$0.25 | -$0.02 | -$0.08 |
Maravai Lifesciences Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | — | — | $575.0M | $322.4M | $216.9M |
| Current Assets | $740.0M | $847.9M | $699.9M | $429.1M | $296.3M |
| Total Assets | $1.92B | $2.28B | $1.49B | $1.01B | $770.6M |
| Current Liabilities | $93.8M | $110.1M | $87.5M | $57.0M | $44.9M |
| Total Long-Term Debt | $530.6M | $527.4M | $524.1M | $295.9M | $291.8M |
| Total Liabilities | $1.37B | $1.38B | $697.6M | $431.0M | $397.9M |
| Shareholders' Equity | $315.5M | $545.2M | $416.8M | $325.3M | $212.4M |
Maravai Lifesciences Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | $368.6M | $536.0M | $126.2M | $7.5M | -$57.6M |
| Cash From Investing | $105.7M | -$267.6M | -$122.3M | -$24.3M | -$31.4M |
| Cash From Financing | -$159.0M | -$187.5M | -$61.1M | -$235.7M | -$16.5M |
| Free Cash Flow | $353.7M | $518.9M | $60.7M | -$22.2M | -$70.7M |
Figures from Maravai Lifesciences' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Maravai Lifesciences financials page for every line item.
Maravai Lifesciences Company Profile
| Ticker | MRVI |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | San Diego, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Accelerated filer |
| SEC CIK | 0001823239 |
Frequently Asked Questions
What was Maravai Lifesciences' revenue in fiscal 2025?
Maravai Lifesciences (MRVI) reported revenue of $185.7M for fiscal 2025.
What is Maravai Lifesciences' annual revenue history?
Maravai Lifesciences' annual revenue by fiscal year: 2021: $799.2M; 2022: $883.0M; 2023: $288.9M; 2024: $259.2M; 2025: $185.7M.
What was Maravai Lifesciences' net income in fiscal 2025?
Maravai Lifesciences reported net income of -$130.8M for fiscal 2025.
What was Maravai Lifesciences' earnings per share (EPS) in fiscal 2025?
Maravai Lifesciences' diluted EPS was -$0.90 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Maravai Lifesciences generate in fiscal 2025?
Maravai Lifesciences generated -$70.7M of free cash flow in fiscal 2025.
What was Maravai Lifesciences' revenue last quarter?
In its most recent reported quarter (2026 Q2), Maravai Lifesciences reported revenue of $51.4M.
How much debt does Maravai Lifesciences have?
Maravai Lifesciences reported $291.8M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Maravai Lifesciences are outstanding?
Maravai Lifesciences reported a weighted average of 148.0 million basic shares outstanding in 2026 Q2.
What is Maravai Lifesciences' market cap?
Based on its latest closing price, Maravai Lifesciences (MRVI) has a market capitalization of about $966.4M.
When does Maravai Lifesciences' fiscal year end?
Maravai Lifesciences' fiscal year end, as registered with the SEC, is December 31.
Where is Maravai Lifesciences headquartered?
Maravai Lifesciences lists its business address in San Diego, California in its SEC filings.